Fresenius SE & Co. KGaA

Investor Presentation • Jan 9, 2017

J.P. Morgan 35th Annual Healthcare Conference

San Francisco, 9 January 2017

Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

A Global Leader In Healthcare Products And Services

Strong, Diversified Product And Service Portfolio

Total Shareholder Return – CAGR, rounded

Source: Bloomberg; dividends reinvested

Fresenius Group: Strong Track Record of Organic Sales Growth in All Business Segments

7% 8% 6% 2% 5% 5% 5% 6% '08 '09 '10 '11 '12 '13 '14 '15

1 – Due to project delays in Russia and Ukraine

Fresenius Group: Consistent Cash Generation And Proven Track Record of Deleveraging

Capex in % of sales

¹ 2011 – 2015 adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)

CFFO margin FCF margin (before acquisitions & dividends)

Acquisition of Quirónsalud: Transaction Highlights

Market leader in size and quality with excellent growth prospects

Strong management team with proven track record and ongoing commitment to Fresenius

Combination forms powerful platform for knowledge & best practice transfer

Substantial cost and growth synergies

Highly accretive from 2017 – leverage back to current levels after 1.5 years

New mid-term targets for Fresenius Group as part of its FY 2016 reporting

Investment Highlights

J.P. Morgan 35th Annual Healthcare Conference

San Francisco, 9 January 2017

Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors